CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
about
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary glandPrognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-AnalysisThe bZIP transcription factor Rca1p is a central regulator of a novel CO₂ sensing pathway in yeast.Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia.HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells.The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancerHypoxia-specific targets in cancer therapy: role of splice variantsClinical biomarkers for hypoxia targetingMembrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancerNoninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes.Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifenThe potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma.Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.Gene expression and hypoxia in breast cancer.Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cellsCytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancerReduction of CAII Expression in Gastric Cancer: Correlation with Invasion and Metastasis.Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.Carbonic anhydrase IX: historical and future perspectives.Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches.The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.Advances in quantitative UV-visible spectroscopy for clinical and pre-clinical application in cancer.Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer.Tumour oxygenation: implications for breast cancer prognosis.Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases.Targeting carbonic anhydrase IX activity and expression.Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer.Targeting aggressive cancers with an artificial sweetener: could saccharin be a lead compound in anticancer therapy?The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.FGF2 as a potential prognostic biomarker for proneural glioma patients.
P2860
Q24669531-A3683F8E-8554-4487-B2DA-9D2B408DAAAAQ26749393-5E60EF31-B3AE-4DFC-93AD-9B1753D2379EQ27932784-845FEA2D-202B-4384-9413-986846B03E62Q30316418-60AB56F8-EE50-4B95-AE1A-16F2B327E3B1Q30318543-A60589DE-7214-4D27-8B35-6802DBABFE3FQ30838633-4CA1DDE5-62F7-41CE-8F1D-F8E598F8B44AQ31130930-C4662E8E-AD33-497C-A98C-BF5FFC0E1C26Q33484460-7FB60575-F59C-431A-8EB4-AE91E4BC0BDDQ33630837-D7232C39-6ECB-4258-82B0-2D2D042730EEQ33714638-2E869B91-D6F2-462E-B750-4127151DA881Q33856008-9AEB6985-347C-41C5-8B47-290B4293F039Q34035225-44092DF6-6244-4AE1-B21F-97920B7D53AAQ34628919-D5582181-411F-447B-A1CF-19356203EC54Q35029556-242D28FD-4423-4DF7-8938-A53C14D565A3Q35037251-014AE5A8-C72E-47E2-B4E3-17813F10608AQ35148025-FD80C39D-D3A6-41CF-A76E-05192490B9EFQ35608684-5BBD7839-0DE9-4763-9D71-33B3AD390CE5Q35614451-99F7CB88-1C51-41F0-A91C-3CD79ADBC662Q35835151-39BE7BEF-E3AA-4D3E-9FD7-289F49990B3BQ35893413-71629293-C804-4D15-84DC-AE25C8D3CE22Q36465353-830C42BF-A2E4-4AF6-8BAC-FF77F3878B6DQ36563177-AB7D4336-41EB-41AE-8A61-62B069FD7EC4Q36678652-1E4890FB-515A-4B28-9B2B-D9208696C4A7Q36965105-89746C4E-4565-4CCB-85C2-AEEB07E22B20Q37038702-4B5AF517-1C18-48AA-9771-A8F3858EA702Q37141969-3915B7AC-F6C4-4124-9808-59038FE42DFAQ37145154-4B703967-4C72-4079-98A9-F38B6ACFD43FQ37145164-BC909C47-4406-4A2A-BC5A-88AD9532991BQ37210542-7342D4D3-BA87-4A00-8870-B3934E61B84BQ37344219-6DF5460C-E47E-4C82-ABA7-2A16585DA00CQ37424052-4E86B332-9AD2-475A-B9C6-FFF357AB2DC7Q38120823-DB403D4D-A293-444C-8070-A86AB859F5EEQ38132855-DCF1AD3E-7279-4564-84BD-56764F439A9EQ38154554-AA7A912B-5545-4FFF-8B29-4991EF6780D5Q38342634-079CA4CD-EB26-469D-9582-9F8E4513CDC9Q38414507-F044AC43-6CE9-4D08-8D2E-534F5C29483DQ38978476-C11A85EF-7D1C-4EEF-8B54-799E0A1FBC62Q39433453-054AC642-FCDD-40F5-811C-C7F3B129470AQ44679006-281851FD-1597-45A7-8602-7F20D8885093Q45084779-7AEB0C87-0A60-4851-961C-2D22603D9A9A
P2860
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
CA IX is an independent progno ...... arker of radiation resistance.
@en
CA IX is an independent progno ...... arker of radiation resistance.
@nl
type
label
CA IX is an independent progno ...... arker of radiation resistance.
@en
CA IX is an independent progno ...... arker of radiation resistance.
@nl
prefLabel
CA IX is an independent progno ...... arker of radiation resistance.
@en
CA IX is an independent progno ...... arker of radiation resistance.
@nl
P2093
P1476
CA IX is an independent progno ...... arker of radiation resistance.
@en
P2093
Asa Kronblad
Donal J Brennan
Goran Landberg
Lisa Rydén
Michael J Duffy
Robert C Millikan
Sallyann L O'Brien
P304
P356
10.1158/1078-0432.CCR-06-0480
P407
P577
2006-11-01T00:00:00Z